Resolvin D1 helps reduce inflammation in heart failure with preserved ejection fraction.
Resolvin D1 resolves inflammation in metabolic stress associated HFpEF
This study is looking at how a special treatment called Resolvin D1 might help people with heart failure who also have inflammation from conditions like obesity and diabetes, with the hope of improving their heart function and overall well-being.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wayne State University NIH-funded |
| Lab location | 1 site (Detroit, United States) |
| Project ID | NIH-10704156 on NIH RePORTER |
What this research studies
This research focuses on heart failure with preserved ejection fraction (HFpEF), a condition affecting many patients and often linked to systemic inflammation from comorbidities like obesity and diabetes. The study aims to explore the therapeutic potential of Resolvin D1, a specialized pro-resolving mediator, to improve inflammation resolution in HFpEF patients. By targeting the underlying inflammatory processes, the research seeks to develop innovative strategies that may enhance heart function and overall patient quality of life.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with heart failure with preserved ejection fraction, particularly those with associated metabolic conditions like obesity and diabetes.
Not a fit: Patients with heart failure with reduced ejection fraction or those without significant metabolic comorbidities may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve the health and quality of life for patients suffering from HFpEF.
How similar studies have performed: While the approach of using specialized pro-resolving mediators like Resolvin D1 is promising, it is relatively novel and has not been extensively tested in the context of HFpEF.
Where this research is happening
Detroit, United States
- Wayne State University — Detroit, United States (Active)
Researchers
- Principal investigator: Palaniyandi, Suresh Selvaraj — Wayne State University
- Study coordinator: Palaniyandi, Suresh Selvaraj
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.